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In healthy humans, high-frequency electrical stimulation (HFS) of the forearm not only 
evokes local signs of central sensitization but also triggers broader ipsilateral inhibitory 
influences on pain akin to a lateralized form of conditioned pain modulation.  Paradoxically, 
some of these inhibitory influences are augmented by α2-adrenoceptor blockade. To 
determine whether opioid peptides mediate inhibitory effects after HFS, the opioid receptor 
antagonist naltrexone was co-administered orally with the α2-adrenoceptor antagonist 
yohimbine in 16 healthy women in a double-blind placebo-controlled crossover study. In 
each session, mechanical sensitivity in the forearms and forehead was assessed before and 
after HFS. In addition, pain ratings to electrical stimulation of HFS-treated or control sites in 
the forearm were assessed during and after painful stimulation of each temple. Unlike 
yohimbine alone, the naltrexone + yohimbine combinatio  blocked analgesia evoked by HFS 
in the ipsilateral forehead to blunt pressure, and opposed the ipsilateral inhibitory effect of 
pain in the temple on electrically-evoked pain at the HFS-treated site in the forearm. These 
findings imply involvement of opioid peptides in anipsilateral analgesic response that 
complements the more generalized form of conditioned pain modulation. Opioid mediation of 
this ipsilateral analgesic response appears to override opposing α2-adrenoceptor effects.   
Perspective: HFS not only evokes local signs of central sensitization but also triggers a 
broader ipsilateral anti-nociceptive mechanism mediat  by opioid receptors.  Dysfunction of 
this lateralized pain modulation process might contribu e to painful unilateral disorders such 
as migraine or complex regional pain syndrome. 
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In healthy humans, high frequency electrical stimulation (HFS) of the forearm, cold-
induced limb pain and heating the capsaicin-sensitised forearm not only induce pain and 
hyperalgesia at and around the site of stimulation but also inhibit sensitivity to blunt pressure 
in the forehead.21,22,48-51  The inhibitory effect persists for up to 60 minutes and is stronger on 
the ipsilateral side, thus resembling a lateralized form of conditioned pain modulation.  
The animal counterpart of conditioned pain modulation, diffuse noxious inhibitory 
controls, involves activation of descending inhibitory pathways from the subnucleus 
reticularis dorsalis in the caudal medulla to the dorsal horn of the spinal cord.47 This 
subnucleus receives nociceptive information from all over the body, and acts to suppress all 
but the strongest sources of pain. Under certain conditi ns, this generalized response appears 
to be supplemented by a lateralized response involving noradrenergic projections from the 
locus coeruleus that drive an inhibitory spinal α2-adrenoceptor mechanism.
41-43  
We previously investigated whether α2-adrenoceptors might also mediate ipsilateral 
analgesia following HFS in humans by administering yohimbine, an α2-adrenoceptor 
antagonist.  However, results were mixed.51  Yohimbine augmented the amplitude of the 
ipsilateral trigeminal nociceptive blink reflex foll wing HFS, consistent with a pro-
nociceptive effect of α2-adrenoceptor blockade. Despite this, yohimbine fail d to block 
analgesia in the ipsilateral forehead to blunt pressure after HFS. In our previous work, a 
conditioning stimulus (cold pain in the temple) inhibited a test stimulus (electrically-evoked 
pain at the HFS-treated site in the forearm) more strongly when the ipsilateral than 
contralateral temple was cooled,48 an effect consistent with inhibitory coeruleospinal 
modulation of sensitized spinal neurons.42,43 Paradoxically, however, yohimbine augmented 















One explanation for these diverse effects is that a blend of adrenergic and non-
adrenergic influences contributes to pain modulation after HFS. These dual influences have 
been identified both in animal and human studies.12,13,53 For example, in rats, contralateral 
capsaicin injection inhibited activity in spinal nociceptors, ostensibly via descending 
inhibitory controls.13 The combination of naloxone (an opioid receptor antagonist) and 
phentolamine (an α1+2-adrenoceptor antagonist) abolished this inhibitory influence, whereas 
either agent alone did not. Thus, multiple inhibitory influences, perhaps elicited 
independently, may converge on spinal projection neurons to block nociceptive 
neurotransmission. 
In the current double-blind placebo-controlled crossover study, the aim was to 
determine whether combined opioid receptor and α2-adrenoceptor blockade would abolish the 
ipsilateral analgesic response triggered by HFS. In particular, yohimbine and an opioid 
receptor antagonist, naltrexone, were co-administered o ally before HFS conditioning. These 
agents enhance pain.3,17,26-29,33,38,40 Thus, we hypothesised that together they would not o ly 
increase primary and secondary hyperalgesia in the forearm but would also inhibit ipsilateral 
analgesia to blunt pressure in the forehead after HFS. We also investigated the effect of 
combined opioid receptor and α2-adrenoceptor blockade on pain ratings to electrical 
stimulation of the HFS-treated site in the forearm during and after painful stimulation of each 
temple. As opioid peptides contribute to conditioned pain modulation,18,30,32,35,38,54 we 
hypothesized that opioid receptor blockade would inhibit the ipsilateral component of this 
response despite an opposing effect of yohimbine.51    
Method 
Participants 
 Males were not included in this study as co-administration of naltrexone and 















not involved in determining the sequence of drug-placebo administration. Exclusion criteria 
included pregnancy, breast-feeding, chronic pain, psychiatric disorders, medical treatment for 
a condition that affected the heart, lungs, blood vessels, skin, liver or kidneys, or a known 
sensitivity to naltrexone or yohimbine. As a result of his screening, two female volunteers 
who took salbutamol for asthma were excluded, leaving a final sample of 16 women aged 
between 18 and 32 years (mean body weight ± standard deviation 59.7 ± 7.3 kg). This was 
considered to be the minimum number required to test th  study hypotheses, based on 
previous studies of HFS.19,20,25,46,48-51  
Recruitment began in February 2014 and data collection finished in July 2015. 
Participants provided their informed consent for the procedures, which were approved by 
Murdoch University’s Human Research Ethics Committee. 
Study design and drug administration  
This study followed a double-blind, placebo-controlled crossover design. Naltrexone 
and yohimbine were co-administered in one session (the first session in five participants) and 
placebo in the other session (the first session in the other 11 participants). The drug-placebo 
order was assigned in no predetermined sequence before the participant arrived by medical 
personnel; thus, neither the experimenter nor the participant was aware of the treatment 
condition during the session. On the day of the experiment, the participant ate a normal 
breakfast and abstained from alcohol and caffeine.  Effects of circadian rhythms were 
controlled by conducting the procedures at the same ti e of day in both sessions. To 
minimise carry-over effects, and to control for menstrual cycle influences on pain, the two 
sessions were separated by 28 days; however, the cycle stage varied across participants. 
Naltrexone hydrochloride (50 mg) (Mallinckrodt Pharm ceuticals, Dublin, Ireland) 
and yohimbine (16 mg) (Pfizer Limited, Tadworth, Surrey, UK) were co-administered orally. 















opioid activity at all three major classes of opioid receptors. Naltrexone and its active 
metabolite 6-beta-naltrexol have half-lives of 4 and 13 hours respectively.  The 50 mg oral 
dose achieves its peak blood concentration within 60 minutes, and can block the effects of 
intravenously-administered opiate drugs for up to 24 h.15 Oral administration of 16 mg of 
yohimbine reverses sedation and anti-nociceptive effects induced by the α2-adrenoceptor  
agonist clonidine.26 Absorption of orally-administered yohimbine is generally complete 
within an hour.39 Despite a relatively short half-life, the cardiovascular effects of orally-
administered yohimbine persist for several hours.39  Thus, it is likely that both drugs were 
maximally active during the experimental period. To maintain blinding, the active drugs and 
the placebo (sugar pellets) were housed within capsules of identical appearance.  
Procedures 
The experimental procedures were similar to those described previously51 
(supplementary Table 1). Each session consisted of three stages (before drug administration, 
after drug administration, and after HFS) and lasted approximately 3 hours. In Stage 1, 
psychophysical tests were administered in the arms nd forehead, and blood pressure and 
heart rate were measured. Stage 2 began with the co-administration of naltrexone + 
yohimbine or placebo.  Sixty minutes later, the psychophysical tests were re-administered, 
and blood pressure and heart rate were reassessed. Stage 3 began 10 minutes after HFS with 
psychophysical tests, followed by an assessment of the effect of painful stimulation of the 
temples on pain to electrical stimulation of the forearm. All test procedures were conducted 
by one experimenter (LV), and participants sat in a comfortable armchair in a quiet room 
maintained at 22 ± 1oC. 
Before the experiment began, the ventral forearms were exfoliated gently with an 
abrasive soap (Solvol, WD40, Australia) to reduce skin electrical resistance.  One ventral 















forearm as the control site. The laterality of the test and control sites was counterbalanced 
across participants.  In the test arm, an area 1 cmfro  the Primary Site was designated the 
Secondary Site to assess secondary hyperalgesia (which reflects central sensitization). 
Psychophysical tests. Participants reported pain or sharpness intensity u ng a verbal 
rating scale ranging from 0 (“no pain” or “not sharp”) to 10 (“extremely painful” or 
“extremely sharp”).  To investigate sensitivity to pinprick in the forearms, participants rated 
sharpness evoked by a sharp tip with a calibrated spring mechanism exerting a force of 40 g 
for 2 seconds (Neuro-pen, Owen Mumford, USA). To measure pressure-pain thresholds 
(PPT), an algometer (FDX, Wagner Instruments, USA) with a modified 8 mm diameter 
hemispheric rubber tip was applied at each forearm site or on each side of the forehead at 100 
g/s until the participant reported pain.  
The psychophysical tests were conducted with each stimulus being applied in runs 
alternating between the test and the control sites, and between the two sides of the forehead, 
in counter-balanced order across participants. To reduce variability in ratings, the participant 
initially was trained in both sessions until ratings and pressure-pain thresholds stabilised. 
Subsequently, each test was performed only once in each round. The exception was during 
baseline when measures taken at two sites on the sam  forearm differed by more than 20% 
(or 2 points on the 0-10 rating scales) or when the participant was uncertain about their 
perception of the initial stimulus. In such cases, the final measurement was the average of 
two readings.  
Blood pressure and heart rate. At each measurement point, systolic blood pressure 
(SBP), diastolic blood pressure (DBP) and heart rate were measured twice two minutes apart 
from the upper arm at heart level using an Omron M4 digital sphygmomanometer that 
detected blood pressure using the oscillometric method. The final reading was the average of 















High-frequency electrical stimulation (HFS). A constant current stimulator (DS7A; 
Digitimer, Welwyn Garden City, UK) was used to generat  the electrical stimuli, which were 
delivered via a custom-built electrode with 25 copper ins.51 A ground plate was attached 1 
cm from the conditioning electrode at a site not used for psychophysical testing. The 
electrical detection threshold (EDT) was determined using the method of limits for 2 
ascending and 2 descending sets of single pulses (2 m  pulse width and an inter-pulse interval 
of 5 s).  The stimulus intensity, starting at 0.1 mA, increased in steps of 0.1 mA until the 
participant perceived the stimulus, and then decreased in steps of 0.05 mA until the stimulus 
was no longer perceived. This procedure was then repeat d. The EDT was defined as the 
geometric mean of the 4 stimulus intensity levels.  
After 5 minutes, HFS conditioning was administered at the test site. This consisted of 
five 1-s bursts of electrical stimulation (100 Hz, 2 ms pulse width, at 10 times EDT up to a 
maximum of 8 mA) with a 9-s rest between each burst. The participant rated pain after each 
burst of stimulation, and the mean rating was calcul ted.   
Pain ratings to electrical stimulation of the forearm during and after painful 
stimulation of each temple. Electrical stimuli (1 Hz and 0.5 ms pulse width) were delivered at 
the HFS-conditioned or control site in the forearm in 96 s runs, via the electrodes used to 
administer HFS, at an intensity which initially evoked a pain level of 5 on the 0-10 verbal 
rating scale. After 32 s of this stimulation (the test stimulus), an ice cube with an application 
surface area of 6 cm2 was held against the left or right temple for 32 s (the conditioning 
stimulus). Participants rated electrically-evoked forearm pain every 2 s for 32 s prior to the 
ice being applied, during the 32-s conditioning period, and for 32 s after the ice was removed 
(the post conditioning period).  In a separate control task, before any temple cooling, 
participants rated electrically-evoked forearm pain every 2 s for 96 s at the HFS and control 















task, to exclude changes that might be due to habitu tion. Test order was counterbalanced 
across participants and temple sides, and alternated between the test and control site in the 
forearms. As ice was applied to each temple twice (once to assess the effect on pain ratings in 
the HFS-treated forearm and once to assess the effect on pain ratings in the control forearm), 
several minutes rest was allowed between each applic tion to minimise carry-over effects.  
Statistical approach 
Drug effects (naltrexone + yohimbine versus placebo) were investigated in 15 
participants who completed both sessions using repeat d-measures analyses of variance 
incorporating planned contrasts from before to after drug administration, and from before 
HFS conditioning (one hour after drug administration) to after HFS conditioning. After HFS, 
changes in sensitivity to sharpness and pressure-pain were compared between the two arms 
(test, control) at the primary and secondary sites, and pressure-pain thresholds were compared 
between the two sides of the forehead (ipsilateral versus contralateral to HFS).  
Changes in electrically-evoked forearm pain during temple cooling were investigated 
in relation to Drug (versus placebo), HFS-conditioning (versus control arm) and Side Cooled 
(ipsilateral versus contralateral to the site of electrical stimulation in the forearm) with simple 
contrasts across Time (baseline versus the conditioing and post conditioning periods). 
 The criterion of statistical significance was p < 0.05. As hypotheses were tested with 
planned contrasts, interactions had only two levels and were investigated further with t-tests. 
Results are presented as the mean ± standard error. 
Results 
Drug side effects 
Only one participant reported side effects during the placebo session (minor nausea). 
However, in the combined naltrexone + yohimbine session, most participants were agitated, 















participants (25%) reported mild headache, and five participants (31%) experienced mild 
nausea and light-headedness. For most participants, symptoms subsided approximately 2 
hours after drug administration. However, nausea intensified in two participants and 
ultimately resulted in vomiting (one shortly after he experiment had concluded and the other 
several hours afterwards). They also felt weak, shaky, nd extremely lethargic, and had pale 
skin, hand tremors, and sharp stomach pain.  These symptoms persisted for more than 6 hours 
after drug administration. Consequently, one of these participants did not return to complete 
the placebo session and her data were excluded from statistical analyses. There was little 
association between the two most common side effects (anxiety and cold hands) and any of 
the pain indices. 
Autonomic activity 
Before drugs were administered, blood pressure and heart rate were similar in the 
drug and placebo sessions (supplementary Fig. 1). One hour after administration, SBP and 
DBP had increased significantly in the combined naltrexone + yohimbine session but not in 
placebo session (SBP: main effect for Drug F(1, 14) = 8.22, p = .012, ηp
2 = 0.37, Drug x Time 
interaction F(1, 14) = 29.2, p < .001, ηp
2 = 0.68; DBP: main effect for Drug F(1, 14) = 8.51, p 
= .011, ηp
2 = 0.38, Drug x Time interaction F(1, 14) = 5.89, p = .029, ηp
2 = 0.30). SBP and 
DBP remained unchanged after HFS conditioning but were higher than in the placebo 
session. 
Heart rate had decreased one hour after drug or placebo administration (main effect 
for Time F(1, 14) = 11.7, p = .004, ηp
2 = 0.46) (supplementary Fig. 1). Heart rate decreased 
further after HFS conditioning (main effect for Time F(1, 14) = 10.4, p = .006, ηp
2 =0.43) but 
more so in the combined naltrexone-yohimbine session than in the placebo session (Drug x 
Time interaction F(1, 14) = 6.44, p = .024, ηp
2 = 0.32) (supplementary Fig. 1).  















Electrical Detection Threshold (EDT). Mean EDT’s were 0.32 ± 0.02 mA and 0.35 ± 
0.03 mA in the combined naltrexone + yohimbine session and placebo session respectively. 
The mean EDT was lower than in a previous study51 in which sites had been prepared with 
dry pumice stone rather than abrasive soap (0.40 ± 0. 2 mA, t(36) = 2.21, p = .034). 
Pain perception to HFS conditioning. The pain induced by HFS conditioning was 
similar in the combined naltrexone + yohimbine session (6.94 ± 0.34 on the 0-10 pain 
intensity scale) and the placebo session (6.64 ± 0.58). 
Primary and secondary hyperalgesia. HFS evoked signs of minor primary and 
secondary hyperalgesia to sharp stimulation, relative to decreases in sharpness in the control 
arm, and also evoked primary hyperalgesia to blunt pressure. Co-administration of naltrexone 
and yohimbine had no consistent effect on primary or secondary hyperalgesia (supplementary 
Fig. 2 and 3). 
Forehead sensitivity 
The pressure-pain threshold (PPT) decreased from before to one hour after drug or 
placebo administration (main effect for Time, F(1, 14) = 9.71, p = .008, ηp
2 =0.41) (Fig. 1).  
After HFS conditioning, the PPT increased (main effect for Time, F(1, 14) = 12.38, p = .003, 
ηp
2 =0.47) but differed between the two sides of the for head (Time x Side interaction, F(1, 
14) = 6.74, p = .021, ηp
2 = 0.33) and sessions (Drug x Time interaction, F(1,14) = 4.98, p = 
.042, ηp
2 = 0.26).   
To clarify the source of the drug effect, changes in the PPT were investigated 
separately in each session. In the placebo session, the PPT increased on both sides of the 
forehead after HFS conditioning, particularly on the ipsilateral side (main effect for Time 
F(1, 14) = 17.64, p = .001, ηp
2 = 0.56, Time x Side interaction F(1, 14) = 17.61, p = .001, ηp
2 
= 0.43). However, the PPT did not change after HFS conditioning in the combined naltrexone 















yohimbine blocked analgesia to blunt pressure triggered by HFS conditioning, particularly in 
the ipsilateral forehead. 
Pain ratings to electrical stimulation of the forearm during and after painful stimulation of 
the temple 
In both sessions the current level required to evok moderate pain in the HFS-
conditioned arm (6.21 ± 0.64 mA) was lower than in the control arm (6.53  ± 0.7 mA) (main 
effect for Arm, F(1, 14) = 5.34, p = .046, ηp
2= .37). Cold-pain ratings in the temples during 
cooling were similar in both sessions (6.7 ± 0.6 in the combined naltrexone + yohimbine 
session and 6.7 ± 0.5 in the placebo session). In the absence of noxious temple cooling,  
ratings of electrically-evoked pain in the forearm decreased from 4.9 ± 0.05 in the first 32 s 
block (equivalent to the period before temple cooling) to 4.4 ± 0.17 in the second block 
(equivalent to the conditioning period) (F(1, 14) = 11.4, p = .005, ηp
2= .45) and to 4.1 ± 0.26 
in the third block (equivalent to the post conditioning period) (F(1, 14) = 10.8, p = .005, ηp
2= 
.44). These decreases were similar in both forearms in both sessions. 
Generally, decreases in electrically-evoked pain in the forearm were greater when ice 
was applied to the ipsilateral than contralateral temple, particularly at the HFS-conditioned 
site (main effect for Side F(1, 14)= 4.73, p = .047, ηp
2= 0.25, Side x Arm interaction F(1, 14) 
= 7.42, p = .016, ηp
2= 0.43, Side x Block [baseline to conditioning period] interaction F(1, 
14) = 6.85, p = .020, ηp
2= 0.33; Side x Block [baseline to post conditioning period] 
interaction F(1, 14) = 7.65, p = .015, ηp
2= 0.35) (Fig. 2).  Importantly, during the 32-s 
conditioning period, electrically-evoked pain at the HFS-treated site decreased in the placebo 
session but increased in the combined naltrexone + yohimbine session (Drug x Arm x Block 
[baseline to conditioning period] interaction F(1, 14) = 6.53, p = .023, ηp
2= 0.32).  
To clarify the effect of naltrexone + yohimbine co-administration, decreases in pain 















condition. In the placebo session, electrically-evoked pain decreased more when ice was 
applied to the ipsilateral than contralateral temple, both at the HFS-treated site (Side x Block 
[baseline to post conditioning period] interaction F(1, 14) = 5.21, p = .039, ηp
2= 0.27) and the 
control site (Side x Block [baseline to post conditioning period] interaction F(1, 14) = 5.72, p 
= .031, ηp
2= 0.29) (Fig. 2).  In contrast, in the combined naltrexone + yohimbine session, 
electrically-evoked pain at the HFS-treated site remained unchanged when ice was applied to 
the ipsilateral temple but increased when ice was applied to the contralateral temple (Side x 
Block [baseline to conditioning period] interaction F(1, 15) = 7.83, p = .014, ηp
2= 0.34); this 
effect persisted during the post conditioning period (Side x Block [baseline to post 
conditioning period] interaction F(1, 15) = 4.94, p = .042, ηp
2= 0.25) (Fig. 2). Painful 
stimulation of the temple had no consistent effect on electrically-evoked pain at the control 
site in the combined naltrexone + yohimbine session. T gether, these findings suggest that 
the co-administration of naltrexone and yohimbine blocked the ipsilateral component of 
conditioned pain modulation at the HFS-treated site in the forearm during the ipsilateral 
conditioning period, and facilitated pain during the contralateral conditioning period.  
Discussion 
We used placebo-controlled combined opioid-receptor and α2-adrenoceptor blockade 
to determine whether opioid receptors were involved in inhibitory pain-modulation processes 
triggered by HFS. Overall, our findings suggest involvement of opioid receptors in anti-
nociceptive processes after HFS (Table 1), but not before HFS was administered.  
Autonomic activity 
One hour after drug administration blood pressure had increased ~4 mm Hg, virtually 
the same as increases after yohimbine alone.51 This might have evoked baroreflex-induced 
hypoalgesia4,7 which, if anything, should have masked the expected pro-nociceptive effects of 















naltrexone + yohimbine condition, indicating that any opposing blood pressure-mediated 
effect was minimal.  
Opioid receptor blockade augments blood pressure during periods of stress (e.g., by 
blocking inhibitory opioid influences on brainstem adrenergic nuclei)45 but has little 
influence on blood pressure under low-stress conditions.11,31 In contrast, administration of 
yohimbine increases autonomic activity and symptoms such as restlessness and agitation 
under low-stress conditions.51 Blocking α2-autoreceptors increases the basal firing rate of 
neurons in brainstem adrenergic nuclei and boosts the release of adrenergic neurotransmitters 
from central and peripheral nerve terminals and somat -dendritic sites.16 Hence, central 
and/or peripheral α2-adrenoceptor blockade probably mediated increases in autonomic 
activity in this study. 
Sensitivity in the forearm  
HFS at 10 or 20 times the individual EDT generally triggers primary and secondary 
hyperalgesia.20,36,48 The presence of only minor primary and secondary hyperalgesia after 
HFS in the present study might have been due to the comparatively low EDT (and hence HFS 
intensity which was administered at ten times the EDT). We used an abrasive soap to 
exfoliate the skin. This was not painful but the soap may have removed skin oils, thereby 
minimising skin impedance and lowering the EDT. Neith r yohimbine alone in our past 
work51 nor co-administration of naltrexone and yohimbine in the present study influenced 
pain evoked by HFS or sensitivity to mechanical stimulation of the forearms before or after 
HFS. Primary and secondary hyperalgesia are thought to reflect sensitization of primary 
afferent nociceptors and spinal wide dynamic range neurons. This sensitization is modulated 
by inhibitory opioid and adrenergic influences.31,33 However, our findings suggest that 
descending inhibitory pain controls were inactive when participants rested quietly, as co-















Alternatively, peripheral and spinal concentrations f yohimbine and naltrexone might not 
have been high enough to block opioid receptors or α2-adrenoceptors involved in modulating 
spinal nociceptive neurotransmission.  
Analgesia to blunt pressure in the forehead  
In the placebo session, sensitivity to blunt pressure decreased on both sides of the 
forehead after HFS of the forearm, with a greater reduction on the ipsilateral side. HFS 
appears to trigger a bilateral inhibitory pain-modulation mechanism (thereby resembling 
conditioned pain modulation) and an additional ipsilateral analgesic process, even in the 
presence of only modest hyperalgesia in the forearm.49 I portantly, naltrexone + yohimbine 
co-administration blocked the analgesic effect of HFS to pressure-pain sensitivity in the 
forehead, suggesting involvement of opioid and/or α2-adrenoceptors in this response.  
Both opioid receptors and α2-adrenoceptors are expressed on primary afferent 
nociceptors, where they play an inhibitory role.34 It seems unlikely, however, that peripheral 
processes involving these receptors mediated ipsilateral analgesia in the forehead after HFS, 
due (i) to the degree of separation between the site of stimulation (the forearm) and analgesia 
(the forehead); and (ii) the laterality of the effect. Opioid peptides exert anti-nociceptive 
effects in the dorsal horn, rostroventral medulla and higher centres, and regulate descending 
anti-nociceptive pathways in the spinal cord.32 Opioid and α2-adrenoceptors are expressed 
widely within the central nervous system, with site of convergence in the dorsal horn, 
brainstem adrenergic nuclei and the midbrain peri-aqueductal grey.1,24,45 Opioids reduce 
nociceptive neurotransmission, in part, by disinhibition of brainstem noradrenergic neurons 
that project to the spinal cord; in turn, anti-nociceptive effects are mediated by spinal α2-
adrenoceptors on primary nociceptive afferents and second-order projection neurons.32 
Numerous animal and human studies have demonstrated syn rgistic interaction between 















effectiveness of tapentadol, a combined µ-opioid receptor agonist and noradrenaline reuptake 
inhibitor.6,37,44 However, our findings suggest that analgesia to blunt pressure in the forehead 
was mediated primarily by opioid receptors as, in our previous work, yohimbine alone was 
ineffective.51 
Pain ratings to electrical stimulation of the forearm during and after painful stimulation of 
the temple 
 In our previous studies, cold-pain in the temple inhibited electrically-evoked forearm 
pain at a HFS-conditioned site.48,51  Furthermore, pain reduction in the forearm was greater 
during ipsilateral than contralateral temple cooling, i dicating the presence of an ipsilateral 
inhibitory pain-modulation process akin to a lateralized form of conditioned pain modulation. 
We observed a similar effect in the placebo session of the present study but not in the 
combined naltrexone + yohimbine session.   
In our past work, yohimbine facilitated the ipsilateral component of this analgesic 
response after HFS, possibly by strengthening descending inhibitory controls.51 However, the 
present findings indicate that additional opioid receptor blockade masked the analgesic 
response, thus supporting the view that opioid peptid s play a primary role not only in the 
generalized form of conditioned pain modulation18,30,32,35,38,54 but also in the lateralized type. 
Methodological Considerations 
Methodological differences, including doses and routes of administration, must be 
considered when comparing the present findings withthose of other studies. We used a single 
low dose of yohimbine to minimise nonspecific effects (mediated, for example, by actions on 
serotonergic, dopaminergic or α1-adrenergic receptors),
14 combined with a dose of naltrexone 
sufficient to block the effects of opiate drugs.15 Thus, we cannot rule out possible 
involvement of non-opioid or α2-adrenoceptor processes in mediating anti-nociceptiv  effects 















blocked certain forms of analgesia triggered by HFS whereas yohimbine alone did not,51 
indicating a predominant role of the opioid system in mediating these effects. 
Yohimbine and naltrexone were administered together, o determine whether 
naltrexone would block the facilitatory effects of y himbine on conditioned pain modulation 
noted in our past work.51 Our findings confirmed that opioid peptides are involved in 
conditioned pain modulation; nevertheless, it is important to investigate effects of naltrexone 
alone in our experimental model, to determine whether opioid receptors act independently of 
α2-adrenoceptors to modify pain. 
As drugs were administered orally, variation in active concentrations over the course 
of the study or from one participant to another might have increased variation in responses. 
The oral route of administration was chosen over th intravenous route to circumvent 
recruitment difficulties. However, pharmacodynamic interactions between yohimbine and 
naltrexone might have influenced the absorption or metabolism of these drugs. Dose-response 
studies involving intravenous administration of drugs would be required to clarify this. 
Nevertheless, the findings suggest that drug levels after oral administration were high enough 
to alter physiological activity, and that naltrexone modified the effects of yohimbine on 
nociceptive processing. 
Although drugs were administered double-blind, it was not always possible to 
maintain blinding due to strong drug-induced side-eff cts such as nausea, agitation and 
headaches.  These side effects might have interfered with the participants’ capacity to 
accurately report pain thresholds and sharpness ratings. However, we are confident that drug 
effects were real because they included influences ot only on psychophysical measures but 
also on conditioned pain modulation. Furthermore, dug effects were limited to the HFS-















As our sample was small, some effects of combined opioid and α2-adrenoceptor 
blockade may have been overlooked due to insufficient statistical power. However, the 
repeated-measures design enabled participants to act as their own control and thus 
compensated, at least in part, for the small sample size.  We have consistently detected HFS-
induced ipsilateral analgesia in mixed gender, healt y populations.21,22,48-51 Still, it is 
important to determine whether disparities in adrene gic or opioid neurotransmission 
contribute to gender differences in pain perception in this experimental model as only 
females were included in this study.  
Finally, certain components of the opioid and adrene gic systems might not have been 
active as most assessments were carried out under resting conditions (perhaps explaining why 
nociceptive effects of naltrexone and yohimbine co-administration were detected only after 
HFS). As inhibitory opioid effects on pain are stronger under stressful or painful than resting 
conditions,9,10 it would be interesting to investigate effects of psychological stress on the 
opioid component of HFS-induced ipsilateral analgesia.   
Conclusions and clinical implications  
Overall, we envisage activation of ipsilateral pain-inhibitory pathways by HFS, and 
that supraspinal and/or spinal endogenous opioid peptides contribute to this response (Fig. 3). 
Conditioned pain modulation is compromised in many chronic pain syndromes, indicative of 
impaired descending inhibitory controls and/or up-regulation of facilitatory controls.2,55 It is 
important to establish whether acute or chronic failure of the lateralised pain modulation 
processes explored in this study underlies symptoms in unilateral disorders such as migraine5 
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Supplementary Table 1. Experimental procedure 
 


















Supplementary Fig. 1. Mean ± S.E. for (a) systolic blood pressure (SBP); (b) diastolic blood 
pressure (DBP); and (c) heart rate at baseline, aftr drug administration and after HFS 
conditioning in the yohimbine + naltrexone and placebo sessions. Blood pressure increased 
after co-administration of yohimbine and naltrexone (# p < .05) but did not change after 
placebo administration. Heart rate remained stable fter co-administration of yohimbine and 
naltrexone but fell after administration of placebo (# p < .05). Blood pressure remained stable 
after HFS in both sessions, but heart rate fell after HFS in the yohimbine + naltrexone session 
(# p < .05). Blood pressure and heart rate were greate  after drug administration in the 
yohimbine + naltrexone session than in the placebo session (* p < .05). 
Supplementary Fig. 2. Mean sharpness ratings ± S.E. to stimulation of the forearm with a 
pin at baseline, after drug administration and after HFS conditioning. Sharpness evoked by 
pinprick remained stable in the test arm after HFS in both sessions, but decreased in the 
control arm (Time x Arm interaction F(1, 14) = 22.5, p < .001, ηp2 = .62) (# p < .05). Co-
administration of yohimbine and naltrexone did not i fluence ratings.  
Supplementary Fig. 3. Mean PPT ± S.E. in the forearm at baseline, after drug administration 
and after HFS. The PPT decreased after HFS during both sessions in the test arm, particularly 
at the primary site, but remained stable in the control arm (Time x Arm interaction F(1, 14) = 
4.78, p = .046, ηp2 = .26, Time x Arm x Site interaction F(1, 14) = 4.52, p = .052, ηp2 = .24). 
Co-administration of yohimbine and naltrexone did not i fluence the PPT. 
Fig. 1. Mean PPT ± S.E. in the ipsilateral and contralateral forehead at baseline, after drug 
administration, and after HFS conditioning. The PPT increased on both sides of the forehead 
after HFS in the placebo session (# p< .05) but did not change after HFS in the naltrexone + 
yohimbine session. In the placebo session, the PPT was higher on the ipsilateral than 
contralateral side of the forehead after HFS (* p < .05). 
Fig. 2. Pain ratings ± S.E. to electrical stimulation of the HFS-conditioned and control sites in 
the forearms during painful stimulation of the ipsilateral and contralateral temples. In the 
placebo session, decreases at the HFS-conditioned site were greater after conditioning the 
ipsilateral than contralateral temple (* p < .05).  
Fig. 3. Schematic representation of the possible involvement of supraspinal opioid receptors 
and α2-adrenoceptors in anti-nociceptive pain modulation processes.  
1. Adrenergic neurons in the locus coeruleus (LC) contribute to descending inhibitory 
controls that inhibit neurotransmission in primary nociceptive afferents (PAN) and 
projection neurons (PN). These adrenergic neurons are active during periods of heightened 
arousal and pain, and are particularly active ipsilateral to painful stimulation of a limb. 
2. Supraspinal inhibitory interneurons (IIN) modulate descending inhibitory controls.32 
3. Opioids block activity in supraspinal inhibitory interneurons, hence releasing descending 
inhibitory controls.32  
4. Yohimbine blocks inhibitory α2-autoreceptors on brainstem adrenergic neurons, thereby 
augmenting descending inhibitory controls.16,52 
5. Naltrexone restores activity in supraspinal inhibitory interneurons, thus inhibiting 
brainstem adrenergic neurons and blocking descending inhibitory controls. 
Point 4 may explain why yohimbine alone strengthened ipsilateral conditioned pain 
modulation in the forearm in our previous work.51 Point 5 might explain why the co-
administration of naltrexone and yohimbine blocked ipsilateral conditioned pain modulation 
in the forearm after HFS in the present study, and also blocked analgesia to pressure-pain in 





















Pre-drug 0 10 Psychophysical test training 
 10 10 First set of psychophysical tests administered 
 20 5 Blood pressure and heart rate measured twice 2 minutes apart 
    
Post-drug 25 60 Naltrexone/yohimbine or placebo administered and absorbed 
 85 10 Second set of psychophysical tests administered 
 95 5 Blood pressure and heart rate measured twice 2 minutes apart 
 100 10 First set of blink reflexes administered (results not reported) 
 110 5 Rest 
 115 5 High Frequency Electrical Stimulation (HFS) administered 
 120 10 Rest 
    
Post-HFS 130 10 Third set  of psychophysical tests administered  
 140 5 Blood pressure and heart rate measured twice 2 minutes apart 
 145 10 Second set of blink reflexes administered (results not reported) 
 155 5 Rest 
 160 25 Pain ratings to electrical stimulation of the forearm during and 















Table 1. Expected and observed effects of HFS in the placebo and naltrexone + yohimbine sessions  
 
 
 Effect of HFS 
Dependent measures Placebo session Naltrexone + yohimbine session 
Pressure-pain threshold (forearm)   
      Expected effect ↓ at the primary site ↓↓ at the primary site 
      Observed effect ↓ trend at the primary site No drug effect  
Sharpness (forearm)   
      Expected effect ↑ at  primary and secondary sites ↑↑ at  primary and secondary sites 
      Observed effect no change in HFS arm but ↓ in control arm No drug effect 
Pressure-pain threshold (forehead)   
      Expected effect ↑ greater on the ipsilateral side ↑ blocked 
      Observed effect ↑ greater on the ipsilateral side ↑ blocked 
Pain ratings to electrical stimulation of 
the forearm during and after painful 
stimulation of each temple 
  
      Expected effect ↓ at the HFS-treated site greater during and after painful 
stimulation of the ipsilateral than contralateral temple  
↓ blocked 
      Observed effect ↓ at the HFS-treated site greater after painful stimulation 






















































• Limb pain evokes an ipsilateral form of conditioned pain modulation  
• Opioid peptides mediate this response in the painful limb and ipsilateral forehead  
• These inhibitory opioid influences override opposing α2-adrenoceptor effects 
• Failure of this ipsilateral opioid response may aggravate chronic limb or head pain  
